OpenOnco · Treatment Plan

Treatment plan — Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

PLAN-VAR-DLBCL-NOS-RELAPSED-V1 · v1 · 2026-05-13

Patient

VAR-DLBCL-NOS-RELAPSED · Algorithm: ALGO-DLBCL-2L

DiagnosisDiffuse Large B-Cell Lymphoma, Not Otherwise Specified

MOH / ICD-10C83.3

ICD-O-39680/3

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

✅ Covered biomarkers (matched in KB)

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

⚠️ Not included in plan

Biomarker	Status
BIO-CD20-IHC	BIO definition in KB; no ESCAT BMA entry — verify with clinician

Primary current-line option

Standard plan

★ DEFAULT

Indication

IND-DLBCL-2L-POLA-R-BENDAMUSTINE

Regimen

Polatuzumab vedotin + Rituximab + Bendamustine (Pola-BR), 6 cycles

Drugs + NSZU

Polatuzumab vedotin (DRUG-POLATUZUMAB-VEDOTIN) 1.8 mg/kg · IV day 2 of cycle 1, day 1 of cycles 2-6 · IV ✗ Not registered in UA
Rituximab (DRUG-RITUXIMAB) 375 mg/m² · IV day 1 of each 21-day cycle · IV ✓ NSZU covered
Bendamustine (DRUG-BENDAMUSTINE) 90 mg/m² · IV days 2-3 of each 21-day cycle · IV ⚠ NSZU — not for this indication

Supportive care

SUP-PJP-PROPHYLAXIS, SUP-HSV-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS, SUP-GCSF-NEUTROPENIA

Hard contraindications

CI-HBV-NO-PROPHYLAXIS, CI-BORTEZOMIB-SEVERE-NEUROPATHY, CI-SEVERE-CYTOPENIA-BR

Reason

Primary current-line option selected by ALGO-DLBCL-2L at step 3.

Other current-line alternatives (1 tracks)

Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.

Aggressive plan

Indication

IND-DLBCL-2L-LISOCEL

Regimen

Lisocabtagene maraleucel (liso-cel) CAR-T 2L for primary-refractory or early-relapse LBCL (TRANSFORM)

Drugs + NSZU

Before main therapy: lymphodepletion — lymphocyte depletion before CAR-T to enable cell engraftment (Flu/Cy days -5 to -3 per TRANSFORM protocol)

Fludarabine (DRUG-FLUDARABINE) 30 mg/m² IV daily × 3 days (lymphodepleting conditioning) · Days -5 to -3 before liso-cel infusion · IV ⚠ NSZU — not for this indication
Cyclophosphamide (DRUG-CYCLOPHOSPHAMIDE) 300 mg/m² IV daily × 3 days (lymphodepleting conditioning) · Days -5 to -3 before liso-cel infusion · IV ⚠ NSZU — not for this indication

Lisocabtagene maraleucel (DRUG-LISOCABTAGENE-MARALEUCEL) Target 100 × 10⁶ CAR+ viable T cells (50 × 10⁶ CD8+ component + 50 × 10⁶ CD4+ component, separately manufactured then administered sequentially) · Single IV infusion day 0, 2-7 days after lymphodepletion completion; CD8 component infused first, followed by CD4 component · IV ✗ Not registered in UA

Supportive care

SUP-PJP-PROPHYLAXIS, SUP-HSV-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS, SUP-IVIG-HYPOGAMMA

Hard contraindications

CI-ACTIVE-INFECTION-FOR-ALEMTUZUMAB, CI-LVEF-LOW-FOR-ANTHRACYCLINE

Reason

Current-line alternative presented for HCP consideration

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks

ID	Name	Priority	Category	Where to order	Needed for
TEST-CBC	Complete Blood Count with Differential	Critical	lab	—	all tracks
TEST-CD20-IHC	CD20 Immunohistochemistry	Critical	histology	CSD Lab ✓ (code TBC)	all tracks
TEST-CMP	Comprehensive Metabolic Panel	Critical	lab	—	all tracks
TEST-FLOW-CYTOMETRY	Flow Cytometry	Critical	histology	CSD Lab ✓ (code TBC)	all tracks
TEST-HBV-SEROLOGY	Hepatitis B Serology Panel (HBsAg, anti-HBc total, anti-HBs)	Critical	lab	—	all tracks
TEST-HCV-ANTIBODY	HCV Antibody	Critical	lab	—	all tracks
TEST-HIV-SEROLOGY	HIV Antibody/Antigen	Critical	lab	—	all tracks
TEST-LDH	Lactate Dehydrogenase	Critical	lab	—	all tracks
TEST-LFT	Liver Function Tests (ALT, AST, bilirubin, ALP, GGT, albumin)	Critical	lab	—	all tracks
TEST-PREGNANCY	Beta-HCG	Critical	lab	—	all tracks
TEST-B2-MICROGLOBULIN	Beta-2 Microglobulin	Standard	lab	—	standard
TEST-ECHO	Echocardiography	Standard	imaging	—	aggressive
TEST-IMMUNOGLOBULINS	Quantitative Immunoglobulins	Standard	lab	—	aggressive
TEST-LN-CORE-BIOPSY	Core LN Biopsy	Standard	histology	—	all tracks
TEST-MRI-BRAIN-CONTRAST	MRI brain with contrast	Standard	imaging	—	aggressive
TEST-PET-CT	FDG PET/CT (whole body)	Standard	imaging	—	all tracks

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track

Composite eligibility for autologous stem-cell transplantation (ASCT) consolidation: ECOG ≤2 AND adequate cardiac function (LVEF ≥50%, no NYHA III-IV) AND adequate pulmonary function (DLCO ≥50% or absent severe COPD/fibrosis) AND adequate hepatic function (bilirubin ≤2× ULN, AST/ALT ≤3× ULN) AND adequate renal function (CrCl ≥30 mL/min) AND age <70 (lymphoma/MM standard) or <65 (AML standard) AND no active uncontrolled infection AND no second active malignancy. Used to gate ASCT consolidation in MM 1L (CASSIOPEIA, GRIFFIN), DLBCL/PTCL salvage (CORAL, ECHELON-2 follow-up), Hodgkin salvage (post-second-line PR/CR), AML CR1 in non-favorable risk if alloHCT donor unavailable. RF-ASCT-ELIGIBLE-COMPOSITE

CONTRA-AGGRESSIVE

Hard contraindications to escalation

Alemtuzumab causes profound, prolonged CD4+ T-cell depletion (median recovery 9-12 months). Active uncontrolled infection at baseline becomes life-threatening once cellular immunity collapses. HIV-positive status is itself an absolute contraindication — alemtuzumab on top of HIV immunosuppression has unacceptable infectious mortality. CI-ACTIVE-INFECTION-FOR-ALEMTUZUMAB
Pre-treatment LVEF <50% is an absolute contraindication to anthracycline-containing regimens (R-CHOP, Pola-R-CHP, ABVD, BV-AVD, etc.). Cardiotoxicity from doxorubicin is dose-cumulative and often irreversible; starting with already-impaired function risks acute decompensation.CI-LVEF-LOW-FOR-ANTHRACYCLINE

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity

Standard plan (IND-DLBCL-2L-POLA-R-BENDAMUSTINE)

Do NOT prescribe with baseline Grade ≥2 peripheral neuropathy — MMAE toxicity will progress to permanent disability.
Do NOT start without HBV screening + entecavir prophylaxis if HBsAg+ or anti-HBc+ — anti-CD20 reactivation.
Do NOT prescribe when CrCl <30 — bendamustine renal-cleared metabolites are dangerous; consider Pola-R without bendamustine.
Do NOT skip GCSF prophylaxis — combined myelosuppression of bendamustine + polatuzumab.
Do NOT prescribe with concomitant strong CYP3A4 inhibitor without monitoring — increased MMAE toxicity.
Do NOT confirm the plan without a verified funding pathway for polatuzumab.
Do NOT use in transplant-eligible patients as 2L — first salvage R-DHAP/R-ICE → autoSCT.

Aggressive plan (IND-DLBCL-2L-LISOCEL)

Do NOT prescribe prophylactic systemic corticosteroids — suppresses CAR-T expansion + reduces efficacy.
Do NOT initiate without on-site tocilizumab (minimum 2 doses) BEFORE infusion — fatal CRS possible.
Do NOT do this at a center without CAR-T accreditation (FACT/JACIE/REMS) — toxicity management requires a specialized team + ICU access.
НЕ пропускати baseline brain MRI — pre-existing CNS disease (CNS-2/3) була exclusion в TRANSFORM; ризик fatal ICANS значно вищий.
Do NOT ignore interim bridging chemotherapy (3-4 week manufacturing window) — disease progression in this window reduces efficacy.
Do NOT prescribe in active uncontrolled infection — lymphodepletion + CRS = high mortality.
Do NOT forget IVIG for long-term hypogammaglobulinemia (IgG <400 + recurrent infections) — B-cell aplasia can persist >12 months.
НЕ застосовувати у транспланта-непридатних пацієнтів за цим показанням — TRANSFORM enrolment вимагав transplant-intent; для transplant-ineligible 2L див. PILOT cohort (окрема Indication, future).

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Polatuzumab vedotin + Rituximab + Bendamustine (Pola-BR), 6 cycles

21-day cycles × 6

MDT brief

Discussion questions (4, 2 blocking)

BLOCKING OQ-CD20-CONFIRMATION
Is CD20+ status confirmed by histology (IHC)? Without CD20+, rituximab/obinutuzumab are not indicated.
Anti-CD20 therapy is the backbone of most lines of treatment; absence of CD20 expression fully changes the regimen.
→ pathologist
OQ-STAGING-COMPLETE
Has complete staging been done (Lugano + PET/CT or CT)?
Prognosis and track selection depend on stage and tumor burden.
→ radiologist
OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist
BLOCKING OQ-BIOMARKER-CD79B-IHC
What is the status of CD79b expression by IHC (target of polatuzumab vedotin) (BIO-CD79B-IHC)? It is required by track(s): IND-DLBCL-2L-POLA-R-BENDAMUSTINE. Expected value: positive (target of polatuzumab vedotin; CD79b expressed in nearly all B-cell lymphomas).
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ pathologist

MDT talk tree (5 steps)

#	Owner	Topic	Action
1	pathologist	Biomarker status BLOCKING	What is the status of CD79b expression by IHC (target of polatuzumab vedotin) (BIO-CD79B-IHC)? It is required by track(s): IND-DLBCL-2L-POLA-R-BENDAMUSTINE. Expected value: positive (target of polatuzumab vedotin; CD79b expressed in nearly all B-cell lymphomas).
2	pathologist	Pathology confirmation BLOCKING	Is CD20+ status confirmed by histology (IHC)? Without CD20+, rituximab/obinutuzumab are not indicated.
3	hematologist	Staging / disease burden	What is the current LDH? Marker of tumor burden and transformation.
4	radiologist	Staging / disease burden	Has complete staging been done (Lugano + PET/CT or CT)?
5	clinical_pharmacist	Specialist review	Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Skills (required) — mandatory virtual specialists (1)

Hematologist / oncohematologist required
Lymphoma diagnosis — leading specialty for treatment management.
Owns: OQ-LDH-CURRENT

Skills (recommended) — for consideration (2)

Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.
Pathologist (general) recommended
Confirm lymphoma histology + assess transformation risk (DLBCL/Richter).
Owns: OQ-CD20-CONFIRMATION, OQ-BIOMARKER-CD79B-IHC

Data quality

Incomplete for default-track review. Default-track review is incomplete until required biomarker gaps are resolved.

Biomarker coverage: 1/2 known (50%), 1 missing, 1 default-track gaps
Missing critical: cd20_ihc_status, lugano_stage
Missing recommended: ldh_ratio_to_uln, fib4_index, pet_ct_date
Unevaluated RedFlags: RF-AAIPI-HIGH, RF-DLBCL-CART-INELIGIBLE-POST-2L, RF-DLBCL-CD20-POS-EPCORITAMAB-CANDIDATE, RF-DLBCL-CD20-POS-GLOFITAMAB-CANDIDATE, RF-DLBCL-CD79B-MUT-MCD-CANDIDATE, RF-DLBCL-CNS-RISK, RF-DLBCL-FRAILTY-AGE, RF-DLBCL-HIGH-IPI, RF-DLBCL-HIGH-RISK-BIOLOGY, RF-DLBCL-INFECTION-SCREENING, RF-DLBCL-ORGAN-DYSFUNCTION, RF-DLBCL-TRANSFORMATION-PROGRESSION, RF-IPI-HIGH, RF-IPI-INTERMEDIATE, RF-IPI-LOW

Missing data for doctor action

Priority	Clinical item	Owner	Why it matters	Next action	Blocks
CRITICAL	CD20 IHC status `cd20_ihc_status`	pathologist	Confirms CD20-directed therapy is biologically appropriate.	Verify CD20 IHC result, specimen, method, and report date.	-
CRITICAL	Lugano stage `lugano_stage`	radiologist	Defines lymphoma extent and supports tumor-burden and response-assessment decisions.	Document Lugano stage from PET/CT or contrast CT staging.	-
RECOMMENDED	LDH ratio to ULN `ldh_ratio_to_uln`	medical_oncologist	Supports prognostic scoring and aggressive-biology flags.	Enter LDH with local upper limit of normal.	-
RECOMMENDED	FIB-4 liver fibrosis index `fib4_index`	infectious_disease_hepatology	Screens hepatic fibrosis risk before hepatotoxic therapy or antiviral coordination.	Calculate FIB-4 from age, AST, ALT, and platelet count.	-
RECOMMENDED	PET/CT date `pet_ct_date`	radiologist	Shows whether baseline staging is recent enough for treatment planning and later response comparison.	Document baseline PET/CT date or explain alternative staging modality.	-

Missing biomarker	Label	MDT owner	Default track	Required by	Next action
`BIO-CD79B-IHC`	CD79b expression by IHC (target of polatuzumab vedotin)	pathologist	yes	IND-DLBCL-2L-POLA-R-BENDAMUSTINE	Verify result, method, specimen, and report date before sign-off. Expected/constraint: positive (target of polatuzumab vedotin; CD79b expressed in nearly all B-cell lymphomas)

Technical MDT skill metadata (3/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-ESMO-LYMPHOMA-2025: Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2025)
SRC-NCCN-BCELL-2025: NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas (v.2.2025)
SRC-TRANSFORM-KAMDAR-2022: Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial (2022)

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-05-13.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT05908409	A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies	PHASE1 / PHASE2	RECRUITING	IDP Discovery Pharma S.L.	—	Small N (<50) Single country
NCT06015880	Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	PHASE1	RECRUITING	National Cancer Institute (NCI)	—	Phase 1 only Small N (<50) Single country
NCT06806033	A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma	PHASE2	RECRUITING	Hoffmann-La Roche	—	—
NCT06536049	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma	PHASE1 / PHASE2	RECRUITING	Yazeed Sawalha	—	Small N (<50) Single country
NCT07097363	Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma	PHASE2	RECRUITING	University of Washington	—	Small N (<50) Single country
NCT06649812	Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma	PHASE2	RECRUITING	National Cancer Institute (NCI)	—	Single country
NCT06287398	Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL	PHASE2	RECRUITING	Australasian Leukaemia and Lymphoma Group	—	Small N (<50) Single country
NCT06486051	A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma	PHASE2	RECRUITING	Malaghan Institute of Medical Research	—	Single country
NCT06784726	Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T	PHASE2	RECRUITING	University of Washington	—	Small N (<50) Single country
NCT07365306	Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	PHASE2	RECRUITING	City of Hope Medical Center	—	Small N (<50) Single country

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Standard plan Polatuzumab vedotin + Rituximab + Bendamustine (Pola-BR), 6 cycles (REG-POLA-R-BENDAMUSTINE) 1/3 component drug(s) not registered in Ukraine +1	✗ not registered	✗ out-of-pocket	₴-? — verify pathway	not recorded
Aggressive plan Lisocabtagene maraleucel (liso-cel) CAR-T 2L for primary-refractory or early-relapse LBCL (TRANSFORM) (REGIMEN-LISOCEL-DLBCL-2L) 1/3 component drug(s) not registered in Ukraine +1	✗ not registered	✗ out-of-pocket	₴-? — verify pathway	not recorded
Trial · NCT05908409 A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06015880 Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06806033 A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06536049 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07097363 Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06649812 Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06287398 Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06486051 A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06784726 Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07365306 Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-05-13.

plan_id: PLAN-VAR-DLBCL-NOS-RELAPSED-V1 | version: 1 | generated: 2026-05-13T10:01:51.890211+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.